All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Sobi's Aspaveli (pegcetacoplan) receives EU approval for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
Protein therapy, rare disease, complement inhibitor, glomerulonephritis, C3 glomerulopathy - Read more

Bayer's Eylea (aflibercept) 8-mg receives EU approval for retinal vein occlusion-related visual impairment
Protein therapy, ophthalmology, VEGF inhibitor, retinal vein occlusion, macular edema - Read more

THE GOOD
Business Development & Partnerships

AbelZeta, AstraZeneca expand GPC3 CAR-T therapy partnership with $630M China rights acquisition
Acquisition, cell therapy, oncology, milestone payments - Read more

Harbour BioMed acquires common stock in Spruce Biosciences, deepening strategic collaboration on SPR202 development
Acquisition, rare disease, antibody, strategic collaboration - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

ImmunityBio reports promising Ph1 results for CD19 CAR-NK cell therapy in Waldenström macroglobulinemia
Cell therapy, cancer, CAR-NK, Waldenström macroglobulinemia, CD19 target, protein therapy - Read more

Johnson & Johnson's CAPLYTA (lumateperone) shows doubled remission rates in Ph3 major depressive disorder analysis
Small molecule, neurological, major depressive disorder, combination therapy, adjunctive treatment - Read more

THE GOOD
Fundraises

AgomAb Therapeutics files $100M US IPO, ALK5 inhibitors for inflammatory diseases
Inflammatory disease, small molecule, gastrointestinal, clinical-stage - Read more

SpyGlass Pharma files $100M IPO, chronic eye condition drug delivery implants
Ophthalmology, drug delivery, clinical-stage, implantable device - Read more

DBV Technologies raises €167M ($193.9M) warrant exercise, VIASKIN Peanut BLA preparation and launch
Allergy immunotherapy, late-stage biopharmaceutical, pediatric treatment, patch technology - Read more

THE GOOD
Market Reports

Novo Nordisk's oral Wegovy shows strong early prescription uptake, outpacing rival Eli Lilly's Zepbound launch
GLP-1 agonist, obesity, competitive, revenue impact - Read more

THE GOOD
Regulatory

European Medicines Agency recommends 104 drugs in 2025, including 38 novel therapies, trailing FDA’s pace but marking second-highest total in 15 years
Regulatory, strategic, competitive, operational - Read more

THE GOOD
Strategic Plans

Novo Nordisk holds 200 J.P. Morgan meetings, refocuses business development strategy after losing Metsera bidding war
GLP-1 receptor agonist, obesity, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

AbbVie, Genmab's Epkinly (epcoritamab) fails Ph3 overall survival endpoint in relapsed refractory diffuse large B-cell lymphoma
Bispecific antibody, cancer, CD3xCD30, diffuse large B-cell lymphoma, relapsed refractory - Read more

THE BAD
Layoffs

Vedanta Biosciences significantly reduces staff, focuses resources on Phase III study of C. diff drug VE303
Oral bacterial medicine, infectious disease, cost reduction, operational - Read more

THE BAD
Politics & Policy

Trump asks Congress to codify 'most favored nation' drug pricing deals with pharmaceutical industry
Pharmaceutical pricing, regulatory, strategic, financial - Read more [Paywall]

THE UGLY
Lawsuits

Former Emergent BioSolutions CEO Robert Kramer sued for insider trading, allegedly gaining $10.1M illegally
Viral vector vaccine, infectious disease, financial, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here